Marshall Wace LLP Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Marshall Wace LLP bought a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 136,491 shares of the company’s stock, valued at approximately $1,454,000. Marshall Wace LLP owned about 0.58% of UroGen Pharma as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Barclays PLC lifted its holdings in shares of UroGen Pharma by 16.0% during the fourth quarter. Barclays PLC now owns 69,325 shares of the company’s stock valued at $738,000 after purchasing an additional 9,547 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of UroGen Pharma during the fourth quarter valued at $1,472,000. Legal & General Group Plc lifted its holdings in shares of UroGen Pharma by 24.6% during the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock valued at $211,000 after purchasing an additional 3,920 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of UroGen Pharma by 2.7% during the fourth quarter. Wells Fargo & Company MN now owns 221,540 shares of the company’s stock valued at $2,359,000 after purchasing an additional 5,801 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of UroGen Pharma during the fourth quarter valued at $358,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Stock Up 14.1 %

URGN opened at $11.26 on Tuesday. UroGen Pharma Ltd. has a fifty-two week low of $8.94 and a fifty-two week high of $20.70. The business has a 50-day moving average of $10.44 and a 200-day moving average of $11.08. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company has a market capitalization of $519.02 million, a PE ratio of -3.57 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Equities research analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on URGN. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of UroGen Pharma in a research report on Monday. The Goldman Sachs Group dropped their price target on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Monday. Scotiabank began coverage on UroGen Pharma in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price target on the stock. Finally, LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, UroGen Pharma has a consensus rating of “Buy” and an average price target of $32.86.

Insider Activity at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.